Axsome Therapeutics Announces Participation in Key Investor Events
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company in the field of central nervous system (CNS) disorders, has recently shared exciting news regarding its participation in several prominent investor conferences set for December. This initiative reflects the company's commitment to fostering deeper connections with investors and promoting its innovative health solutions.
Upcoming Conferences and Engagements
Among the notable events, Axsome Therapeutics will feature at the renowned:
Piper Sandler 37th Annual Healthcare Conference
The company is scheduled for a fireside chat on Wednesday, December 3, 2025, at 4:00 p.m. ET. This interactive session will allow investors to gain insights into Axsome's current projects and future directions.
BofA Securities CNS Therapeutics Virtual Conference 2025
On Monday, December 8, 2025, at 11:40 a.m. ET, Axsome will engage in a fireside chat highlighting its ongoing innovations and developments in the therapeutic realm.
Access to Live Events
For those unable to attend in person, Axsome Therapeutics is making it easier to stay informed. A live webcast of the Piper Sandler presentation will be available under the "Webcasts & Presentations" section on the company’s official website. Investors can also look forward to a replay accessible for approximately 30 days after the event, ensuring everyone has the opportunity to engage with the material.
About Axsome Therapeutics
Axsome Therapeutics stands at the forefront of biopharmaceutical innovation, with a strong focus on central nervous system conditions. The company has dedicated itself to delivering groundbreaking treatments that bridge the gaps in existing care. Their portfolio includes FDA-approved therapies for major depressive disorder, excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea, and migraine treatments. Furthermore, Axsome is involved in developing numerous early and late-stage programs targeting a wide array of serious neurological and psychiatric issues affecting over 150 million individuals in the U.S. Through their relentless pursuit of solutions, Axsome aims to transform patient lives.
Contacting Axsome Therapeutics
For inquiries about investment opportunities or media relations, Axsome Therapeutics provides direct communication lines:
Investors Contact
Ashley Dong
Director, Investor Relations
(929) 687-1614
For email inquiries, please contact adong@axsome.com.
Media Contact
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
Email can be sent to dopland@axsome.com.
Frequently Asked Questions
What is Axsome Therapeutics known for?
Axsome Therapeutics is recognized for its innovative treatments for central nervous system disorders, emphasizing impactful therapies that improve patient outcomes.
When will Axsome present at the Piper Sandler conference?
Axsome is set to present on December 3, 2025, at 4:00 p.m. ET during the Piper Sandler 37th Annual Healthcare Conference.
Will there be a replay of the conference events?
Yes, a replay of the Piper Sandler presentation will be available on the company’s website for about 30 days following the event.
How can investors stay updated on Axsome’s developments?
Investors can access updates through Axsome's website, particularly the Webcasts & Presentations section, and follow company news releases and social media profiles.
Who can I contact for more information regarding Axsome?
For investor inquiries, contact Ashley Dong, and for media-related questions, reach out to Darren Opland via the contact information provided.